Select Publications
Journal articles
2024, 'Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.', J Natl Compr Canc Netw, 22, pp. 108 - 116, http://dx.doi.org/10.6004/jnccn.2023.7083
,2024, 'Upper-limb dysfunction in cancer survivors with chemotherapy-induced peripheral neurotoxicity', Journal of the Neurological Sciences, 457, http://dx.doi.org/10.1016/j.jns.2023.122862
,2024, 'Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial', Nature Medicine, 30, pp. 498 - 506, http://dx.doi.org/10.1038/s41591-023-02734-5
,2024, 'Abstract B062: CRO67 has therapeutic potential against pancreatic tumor cells and cancer associated fibroblasts', Cancer Research, 84, pp. B062 - B062, http://dx.doi.org/10.1158/1538-7445.panca2023-b062
,2024, 'Sleep dysfunction associated with worse chemotherapy-induced peripheral neurotoxicity functional outcomes', Supportive Care in Cancer, 32, http://dx.doi.org/10.1007/s00520-023-08245-w
,2023, 'INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)', BMC Cancer, 23, http://dx.doi.org/10.1186/s12885-023-10642-7
,2023, 'Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group', Journal of Clinical Oncology, 41, pp. 4714 - 4720, http://dx.doi.org/10.1200/JCO.22.02770
,2023, 'The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative', Cancer, 129, pp. 3263 - 3274, http://dx.doi.org/10.1002/cncr.34932
,2023, 'Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study', European Journal of Cancer, 192, http://dx.doi.org/10.1016/j.ejca.2023.113245
,2023, 'A Matched Molecular and Clinical Analysis of the Epithelioid Haemangioendothelioma Cohort in the Stafford Fox Rare Cancer Program and Contextual Literature Review', Cancers, 15, http://dx.doi.org/10.3390/cancers15174378
,2023, 'Quantifying Neck Fibrosis: Establishing the Domain Structure of the Neck Fibrosis Scale', Laryngoscope, 133, pp. 2198 - 2202, http://dx.doi.org/10.1002/lary.30497
,2023, 'HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis', Cancer Letters, 568, http://dx.doi.org/10.1016/j.canlet.2023.216286
,2023, 'Glossectomy for the treatment of oral cavity carcinoma: Quantitative, functional and patient-reported quality of life outcomes differ by four glossectomy defects', Oral Oncology, 142, http://dx.doi.org/10.1016/j.oraloncology.2023.106431
,2023, 'The effect of exercise intensity on the inflammatory profile of cancer survivors: A randomised crossover study', European Journal of Clinical Investigation, 53, http://dx.doi.org/10.1111/eci.13984
,2023, 'Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer', Journal of Cancer Research and Clinical Oncology, 149, pp. 4959 - 4965, http://dx.doi.org/10.1007/s00432-022-04404-4
,2023, 'Targeting translation: A review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy', Journal of the Peripheral Nervous System, 28, pp. 179 - 190, http://dx.doi.org/10.1111/jns.12544
,2023, 'Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 41, pp. 2007 - 2019, http://dx.doi.org/10.1200/JCO.22.01134
,2023, 'Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial', eClinicalMedicine, 58, http://dx.doi.org/10.1016/j.eclinm.2023.101897
,2023, 'Progress in the Treatment of Small Intestine Cancer', Current Treatment Options in Oncology, 24, pp. 241 - 261, http://dx.doi.org/10.1007/s11864-023-01058-3
,2023, 'Irradiation-Induced Dysbiosis: The Compounding Effect ofHigh-Fat Diet on Metabolic and Immune Functions in Mice', International Journal of Molecular Sciences, 24, pp. 5631 - 5631, http://dx.doi.org/10.3390/ijms24065631
,2023, 'Practice patterns for positive sentinel lymph node in head and neck melanoma', Head and Neck, 45, pp. 555 - 560, http://dx.doi.org/10.1002/hed.27262
,2023, 'ASCO's Leadership Development Program: Focusing on the Next Generation of Leaders in Asia Pacific', JCO global oncology, 9, pp. e2200313, http://dx.doi.org/10.1200/GO.22.00313
,2023, 'INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).', Journal of Clinical Oncology, 41, pp. LBA294 - LBA294, http://dx.doi.org/10.1200/jco.2023.41.4_suppl.lba294
,2023, 'Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review', Journal of Cancer Survivorship, 17, pp. 222 - 236, http://dx.doi.org/10.1007/s11764-021-00988-x
,2023, 'Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes', JNCCN Journal of the National Comprehensive Cancer Network, 21, pp. 125 - 132, http://dx.doi.org/10.6004/jnccn.2022.7074
,2023, 'Physical activity behaviors in cancer survivors treated with neurotoxic chemotherapy', Asia-Pacific Journal of Clinical Oncology, 19, pp. 243 - 249, http://dx.doi.org/10.1111/ajco.13834
,2023, 'Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors', Journal for ImmunoTherapy of Cancer, 11, http://dx.doi.org/10.1136/jitc-2022-006136
,2023, 'Associations between Human Papillomavirus Status, Weight Change, and Survival of Oropharyngeal Cancer Patients', Nutrition and Cancer, 75, pp. 1541 - 1550, http://dx.doi.org/10.1080/01635581.2023.2212427
,2023, 'C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients', Asia-Pacific Journal of Clinical Oncology, http://dx.doi.org/10.1111/ajco.13993
,2022, 'Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)', Frontiers in Immunology, 13, http://dx.doi.org/10.3389/fimmu.2022.1060957
,2022, 'Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients', Clinical Autonomic Research, 32, pp. 497 - 506, http://dx.doi.org/10.1007/s10286-022-00895-w
,2022, 'Clinical and molecular profile of young adults with early-onset colorectal cancer: Experience from four Australian tertiary centers', Asia-Pacific Journal of Clinical Oncology, 18, pp. 660 - 668, http://dx.doi.org/10.1111/ajco.13745
,2022, 'Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study', Journal of Translational Medicine, 20, http://dx.doi.org/10.1186/s12967-022-03754-4
,2022, 'Reproducibility and Reliability of Subbasal Corneal Nerve Parameters of the Inferior Whorl in the Neurotoxic and Healthy Cornea', Cornea, 41, pp. 1487 - 1494, http://dx.doi.org/10.1097/ICO.0000000000002947
,2022, 'Abstract B076: βIII-Tubulin is a brake on extrinsic cell-death in pancreatic cancer', Cancer Research, 82, pp. B076 - B076, http://dx.doi.org/10.1158/1538-7445.panca22-b076
,2022, 'Abstract C073: CRO-67 is a novel therapeutic for pancreatic cancer: Implications for tumor and stromal reprogramming', Cancer Research, 82, pp. C073 - C073, http://dx.doi.org/10.1158/1538-7445.panca22-c073
,2022, 'Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use', Quality of Life Research, 31, pp. 3091 - 3107, http://dx.doi.org/10.1007/s11136-022-03154-7
,2022, 'Tear film substance P in patients treated with neurotoxic chemotherapy', Experimental Eye Research, 224, http://dx.doi.org/10.1016/j.exer.2022.109253
,2022, 'What is the gender representation in authorship in later phase systemic clinical trials in biliary tract cancer (BTC)? - a retrospective review of the published literature', BMJ Open, 12, http://dx.doi.org/10.1136/bmjopen-2022-064954
,2022, 'Return of comprehensive tumour genomic profiling results to advanced cancer patients: a qualitative study', Supportive Care in Cancer, 30, pp. 8201 - 8210, http://dx.doi.org/10.1007/s00520-022-07272-3
,2022, 'Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy', Supportive Care in Cancer, 30, pp. 5965 - 5974, http://dx.doi.org/10.1007/s00520-022-07024-3
,2022, 'Psychological impact of comprehensive tumor genomic profiling results for advanced cancer patients', Patient Education and Counseling, 105, pp. 2206 - 2216, http://dx.doi.org/10.1016/j.pec.2022.01.011
,2022, 'Destructive soft tissue metastases in advanced colorectal cancer: a case report', Annals of Palliative Medicine, 11, pp. 2170 - 2174, http://dx.doi.org/10.21037/apm-21-362
,2022, 'The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer', HPB, 24, pp. 950 - 962, http://dx.doi.org/10.1016/j.hpb.2021.11.005
,2022, 'The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors', Journal of Cancer Survivorship, 16, pp. 223 - 232, http://dx.doi.org/10.1007/s11764-021-01012-y
,2022, 'Genetic and genomic learning needs of oncologists and oncology nurses in the era of precision medicine: A scoping review', Personalized Medicine, 19, pp. 139 - 153, http://dx.doi.org/10.2217/pme-2021-0096
,2022, 'Psychological predictors of advanced cancer patients’ preferences for return of results from comprehensive tumor genomic profiling', American Journal of Medical Genetics, Part A, 188, pp. 725 - 734, http://dx.doi.org/10.1002/ajmg.a.62563
,2022, 'The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours', Targeted Oncology, 17, pp. 95 - 110, http://dx.doi.org/10.1007/s11523-022-00869-y
,2022, 'Corrigendum to “Evidence of slow and variable choice-stepping reaction time in cancer survivors with chemotherapy-induced peripheral neuropathy” [Gait Posture 89 (2021) 178–185](S0966636221002514)(10.1016/j.gaitpost.2021.07.010)', Gait and Posture, 92, pp. 1, http://dx.doi.org/10.1016/j.gaitpost.2021.11.006
,2022, 'Effectively communicating comprehensive tumor genomic profiling results: Mitigating uncertainty for advanced cancer patients', Patient Education and Counseling, 105, pp. 452 - 459, http://dx.doi.org/10.1016/j.pec.2021.05.018
,